Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.

Andersson KE.

Ther Clin Risk Manag. 2013;9:161-70. doi: 10.2147/TCRM.S33052. Epub 2013 Apr 18.

2.

Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.

Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, Odeyemi I, Hakimi Z.

Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18. Review.

PMID:
24275310
3.

Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).

Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V.

BJU Int. 2015 Jan;115(1):32-40. doi: 10.1111/bju.12730. Epub 2014 Jul 27. Review.

4.

Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.

Blais AS, Nadeau G, Moore K, Genois L, Bolduc S.

Eur Urol. 2016 Jul;70(1):9-13. doi: 10.1016/j.eururo.2016.02.007. Epub 2016 Feb 11.

PMID:
26876327
5.

Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial.

Khullar V, Cambronero J, Angulo JC, Wooning M, Blauwet MB, Dorrepaal C, Martin NE.

BMC Urol. 2013 Sep 18;13:45. doi: 10.1186/1471-2490-13-45.

6.

A drug safety evaluation of mirabegron in the management of overactive bladder.

Robinson D, Thiagamoorthy G, Cardozo L.

Expert Opin Drug Saf. 2016 May;15(5):689-96. doi: 10.1517/14740338.2016.1165663. Epub 2016 Apr 21. Review.

PMID:
26980445
7.

Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.

Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T.

Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17. Review.

PMID:
26828974
8.

β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.

Otsuki H, Kosaka T, Nakamura K, Mishima J, Kuwahara Y, Tsukamoto T.

Int Urol Nephrol. 2013 Feb;45(1):53-60. doi: 10.1007/s11255-012-0343-5. Epub 2012 Dec 2.

PMID:
23212147
9.

What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?

Caremel R, Loutochin O, Corcos J.

Int Urogynecol J. 2014 Feb;25(2):165-70. doi: 10.1007/s00192-013-2161-4. Epub 2013 Aug 7. Review.

PMID:
23922008
10.
11.

Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.

Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC.

Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11. Review.

PMID:
24127366
12.

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.

J Manag Care Spec Pharm. 2016 Sep;22(9):1072-84. doi: 10.18553/jmcp.2016.22.9.1072.

13.

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.

J Manag Care Spec Pharm. 2016 Sep;22(9):1076-90. doi: 10.18553/jmcp.2016.22.9.1076.

14.
15.

Pharmacotherapy of the overactive bladder.

Andersson KE.

Discov Med. 2009 Oct;8(42):118-24.

16.

[Developments in the medical treatment of overactive bladder].

Alcántara Montero A.

Semergen. 2016 Nov - Dec;42(8):557-565. doi: 10.1016/j.semerg.2015.10.006. Epub 2015 Dec 4. Spanish.

PMID:
26671329
17.

Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.

Jayarajan J, Radomski SB.

Res Rep Urol. 2013 Dec 6;6:1-16. doi: 10.2147/RRU.S40034. Review.

18.

Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.

Hakimi Z, Nazir J, McCrea C, Berling M, Fatoye F, Ramos B, Wagg A.

J Med Econ. 2017 Mar 12:1-9. doi: 10.1080/13696998.2017.1294595. [Epub ahead of print]

PMID:
28286993
19.

Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.

Angulo JC, Khullar V, Nitti VW, Siddiqui E.

Actas Urol Esp. 2013 Nov-Dec;37(10):640-51. doi: 10.1016/j.acuro.2013.05.003. Epub 2013 Jul 12. Review.

PMID:
23850394
20.

A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.

Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, Suehs BT.

Neurourol Urodyn. 2017 Mar 31. doi: 10.1002/nau.23271. [Epub ahead of print]

PMID:
28370541

Supplemental Content

Support Center